HomeSectorLife SciencesHybrid financing in life sciences

Hybrid financing in life sciences

-

Unlocking growth amid market challenges

High interest rates and tighter capital have changed how life sciences companies fund growth and innovation. Equity alone is no longer the default, and many biotech and MedTech companies are turning to hybrid financing to keep programs moving without giving up control too early.

Provide your email address to continue reading

For unlimited free access to all articles and analysis from the past month

Or to access 5,700+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Already have an account?
McDermott Will & Schulte
McDermott Will & Schultehttps://www.mcdermottlaw.com/
McDermott Will & Schulte’s internationally recognized healthcare and life sciences practice addresses the critical legal and business needs of leading industry players. You can turn to us to drive innovative deals and navigate high-stakes disputes, enforcement risks, and complex regulatory issues. Our global team leverages deep market intelligence and decades of experience representing clients across all subsectors, including health systems and other providers, payors, private equity and other investors, major healthcare and life sciences companies, health technology developers, and new market entrants. Serving as a convener, we foster meaningful partnerships and thought leadership through our premier conferences. You also benefit from our exclusive affiliation with healthcare policy and advocacy firm McDermott+, which helps you navigate legislative and regulatory obstacles to maintain competitive advantage. We stand as the only healthcare practice to receive top rankings from Best Law Firms, Chambers, Legal 500, and Law360 (which has named us “Practice Group of the Year for Healthcare” multiple times), while also ranking among the leading life sciences law firms. When you work with us, Always Better isn’t just our goal – it’s your advantage.
Related Articles
More From Author

…

Provide your email address to continue reading

For unlimited free access to all articles and analysis from the past month

Or to access 5,700+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Already have an account?

…

Provide your email address to continue reading

For unlimited free access to all articles and analysis from the past month

Or to access 5,700+ articles from an archive of 7 years plus data tables on M&A, Equity, Debt and more

Already have an account?
Advertisement

Related Resources

Related Events